Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) and licensor SERB reached a settlement with Hetero and affiliates resolving patent litigation over FIRDAPSE (amifampridine) 10 mg tablets. Under the Agreement, Hetero may not market a U.S. generic earlier than a specified date in January 2035, if FDA-approved. All related U.S. district court cases will be terminated before the May 18, 2026 trial date, and the confidential settlement will be submitted to the U.S. FTC and DOJ for review.
AI-generated analysis. Not financial advice.
Positive
- Settlement resolves all pending FIRDAPSE patent litigation
- Hetero blocked from U.S. marketing until January 2035
- Ongoing litigation terminated before May 18, 2026 trial
Negative
- Generic entry possible in the U.S. as early as January 2035
- Settlement agreement subject to FTC and DOJ review
News Market Reaction – CPRX
On the day this news was published, CPRX gained 2.11%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CPRX was down 1.1% while peers showed mixed, mostly modest moves (e.g., FOLD +0.07%, CELC -0.81%, IBRX +8.83%), with no momentum-clustered sector move flagged.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Earnings date notice | Neutral | +0.6% | Announced timing of Q1 2026 results release and conference call. |
| Mar 06 | Medical conference plans | Neutral | -0.3% | Detailed DMD real-world data posters and a vamorolone-focused symposium. |
| Feb 25 | Earnings and guidance | Positive | +2.8% | Reported record 2025 revenues and net income with higher 2026 guidance and buybacks. |
| Feb 24 | Conference participation | Neutral | +0.3% | Announced presentation at Barclays Global Healthcare Conference and webcast access. |
| Feb 11 | Earnings date notice | Neutral | -1.4% | Scheduled Q4 and full-year 2025 results release and follow-up call. |
Record earnings and guidance updates have drawn clearly positive reactions, while scheduling and conference-related news have produced only modest, mixed price moves.
Over the past several months, Catalyst has highlighted record 2025 financial results, with total revenues of $589.0 million and GAAP net income of $214.3 million, alongside 2026 revenue guidance of $615–$645 million. Earnings-related news on Feb 25, 2026 coincided with a 2.77% gain, contrasting with smaller, mixed moves around conference and earnings-date announcements. Today’s patent-litigation settlement on FIRDAPSE fits into this broader pattern of managing IP and lifecycle risks around its key rare-disease portfolio.
Market Pulse Summary
This announcement settles patent litigation over FIRDAPSE by granting Hetero a license to market a generic version no earlier than January 2035, subject to FDA approval and customary conditions. It removes a scheduled trial set for May 18, 2026 and leaves Catalyst with no remaining FIRDAPSE patent suits. Investors may monitor future IP developments, generic challenges in other products, and how this long-dated generic pathway interacts with the company’s broader rare-disease strategy.
Key Terms
abbreviated new drug application regulatory
u.s. food and drug administration regulatory
AI-generated analysis. Not financial advice.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035
Catalyst has No Other FIRDAPSE Patent Litigation Pending
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (“Agreement”) with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private Limited (collectively, Hetero). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Hetero’s Abbreviated New Drug Application (“ANDA”) seeking approval to market a generic version of FIRDAPSE® (amifampridine) 10 mg tablets prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Hetero will not market its generic version of FIRDAPSE in the United States any earlier than a specified date in January 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Hetero regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey prior to the scheduled trial commencement on May 18, 2026. Catalyst previously settled similar litigation regarding ANDA applications for FIRDAPSE with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited. This settlement resolves all pending patent litigation relating to FIRDAPSE.
As required by law, the companies will submit the confidential settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2025 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact Jed Repko / Mahmoud Siddig Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449